Chen X - Search Results

1

Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients.

Chen Y, Jiang Y, Qu J, Wang Q, Bai Y, Shi J, Shi Y, Chen X, Yang N, Heng J, Li K. Chen Y, et al. Among authors: chen x. Eur J Pharm Sci. 2020 Aug 1;151:105384. doi: 10.1016/j.ejps.2020.105384. Epub 2020 May 26. Eur J Pharm Sci. 2020. PMID: 32470574 Clinical Trial.

2

Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.

Heng J, Tang Q, Chen X, Bao J, Deng J, Chen Y, Zhao J, Zhu S, Liu X, Yang F, Jiang Y, Yang N, Li K. Heng J, et al. Among authors: chen x, chen y. Eur J Pharm Sci. 2021 Jul 1;162:105815. doi: 10.1016/j.ejps.2021.105815. Epub 2021 Mar 23. Eur J Pharm Sci. 2021. PMID: 33771716 Clinical Trial.

3

Corrigendum to ' Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers'[European Journal of Pharmaceutical Sciences 162 (2021) 105815].

Heng J, Tang Q, Chen X, Bao J, Deng J, Chen Y, Zhao J, Zhu S, Liu X, Yang F, Jiang Y, Yang N, Li K. Heng J, et al. Among authors: chen x, chen y. Eur J Pharm Sci. 2022 Apr 1;171:106143. doi: 10.1016/j.ejps.2022.106143. Epub 2022 Feb 16. Eur J Pharm Sci. 2022. PMID: 35181200 Free article. No abstract available.

4

A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects.

Zhu S, Deng J, Tang Q, Heng J, Qu J, Chen Y, Chen X, Yang N, Liu X, Li K. Zhu S, et al. Among authors: chen x, chen y. Iran J Pharm Res. 2020 Summer;19(3):24-33. doi: 10.22037/ijpr.2020.113112.14116. Iran J Pharm Res. 2020. PMID: 33680007 Free PMC article.

5

Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.

Chen X, Yang F, Zhao J, Tang Q, Heng J, Deng J, Zhang J, Chen Y, Li K, Wang J. Chen X, et al. Among authors: chen y. Cancer Chemother Pharmacol. 2022 Jan;89(1):141-148. doi: 10.1007/s00280-021-04376-1. Epub 2021 Dec 1. Cancer Chemother Pharmacol. 2022. PMID: 34851444

6

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

Qu J, Zhang Y, Chen X, Yang H, Zhou C, Yang N. Qu J, et al. Among authors: chen x. Oncotarget. 2017 Dec 26;9(11):10147-10163. doi: 10.18632/oncotarget.23755. eCollection 2018 Feb 9. Oncotarget. 2017. PMID: 29515799 Free PMC article. Review.

7

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy.

Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Jing Y, et al. Among authors: chen x. J Natl Cancer Inst. 2021 Oct 1;113(10):1396-1404. doi: 10.1093/jnci/djab035. J Natl Cancer Inst. 2021. PMID: 33705549

8

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy.

Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X, Liu H, Han L. Jing Y, et al. Among authors: chen x, chen y. J Immunother Cancer. 2022 Jan;10(1):e003779. doi: 10.1136/jitc-2021-003779. J Immunother Cancer. 2022. PMID: 35058327 Free PMC article.

9

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.

Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J. Hong T, et al. Among authors: chen x. Redox Biol. 2021 Jun;42:101928. doi: 10.1016/j.redox.2021.101928. Epub 2021 Mar 5. Redox Biol. 2021. PMID: 33722571 Free PMC article.

10

TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation.

Chen Y, Liu L, Xia L, Wu N, Wang Y, Li H, Chen X, Zhang X, Liu Z, Zhu M, Liao Q, Wang J. Chen Y, et al. Among authors: chen x. J Exp Clin Cancer Res. 2022 Jan 31;41(1):44. doi: 10.1186/s13046-022-02252-1. J Exp Clin Cancer Res. 2022. PMID: 35101076 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117,044 results

Search Page

Filters